428 related articles for article (PubMed ID: 16728647)
1. Deletion of the alpha7, beta2, or beta4 nicotinic receptor subunit genes identifies highly expressed subtypes with relatively low affinity for [3H]epibatidine.
Marks MJ; Whiteaker P; Collins AC
Mol Pharmacol; 2006 Sep; 70(3):947-59. PubMed ID: 16728647
[TBL] [Abstract][Full Text] [Related]
2. Gene targeting demonstrates that alpha4 nicotinic acetylcholine receptor subunits contribute to expression of diverse [3H]epibatidine binding sites and components of biphasic 86Rb+ efflux with high and low sensitivity to stimulation by acetylcholine.
Marks MJ; Meinerz NM; Drago J; Collins AC
Neuropharmacology; 2007 Sep; 53(3):390-405. PubMed ID: 17631923
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of the beta4 neuronal nicotinic receptor subunit affects tolerance development and nicotinic binding sites following chronic nicotine treatment.
Meyers EE; Loetz EC; Marks MJ
Pharmacol Biochem Behav; 2015 Mar; 130():1-8. PubMed ID: 25560939
[TBL] [Abstract][Full Text] [Related]
4. Nicotinic-agonist stimulated (86)Rb(+) efflux and [(3)H]epibatidine binding of mice differing in beta2 genotype.
Marks MJ; Stitzel JA; Grady SR; Picciotto MR; Changeux JP; Collins AC
Neuropharmacology; 2000 Oct; 39(13):2632-45. PubMed ID: 11044733
[TBL] [Abstract][Full Text] [Related]
5. Identification of a novel nicotinic binding site in mouse brain using [(125)I]-epibatidine.
Whiteaker P; Jimenez M; McIntosh JM; Collins AC; Marks MJ
Br J Pharmacol; 2000 Oct; 131(4):729-39. PubMed ID: 11030722
[TBL] [Abstract][Full Text] [Related]
6. Localization of [3H]nicotine, [3H]cytisine, [3H]epibatidine, and [125I]alpha-bungarotoxin binding sites in the brain of Macaca mulatta.
Han ZY; Zoli M; Cardona A; Bourgeois JP; Changeux JP; Le Novère N
J Comp Neurol; 2003 Jun; 461(1):49-60. PubMed ID: 12722104
[TBL] [Abstract][Full Text] [Related]
7. Long-term exposure to the new nicotinic antagonist 1,2-bisN-cytisinylethane upregulates nicotinic receptor subtypes of SH-SY5Y human neuroblastoma cells.
Riganti L; Matteoni C; Di Angelantonio S; Nistri A; Gaimarri A; Sparatore F; Canu-Boido C; Clementi F; Gotti C
Br J Pharmacol; 2005 Dec; 146(8):1096-109. PubMed ID: 16273122
[TBL] [Abstract][Full Text] [Related]
8. Characterization of [(125) I]epibatidine binding and nicotinic agonist-mediated (86) Rb(+) efflux in interpeduncular nucleus and inferior colliculus of beta2 null mutant mice.
Marks MJ; Whiteaker P; Grady SR; Picciotto MR; McIntosh JM; Collins AC
J Neurochem; 2002 Jun; 81(5):1102-15. PubMed ID: 12065623
[TBL] [Abstract][Full Text] [Related]
9. In vivo effects of 3-iodocytisine: pharmacological and genetic analysis of hypothermia and evaluation of chronic treatment on nicotinic binding sites.
Zambrano CA; Marks MJ; Cassels BK; Maccioni RB
Neuropharmacology; 2009 Sep; 57(3):332-42. PubMed ID: 19481555
[TBL] [Abstract][Full Text] [Related]
10. High-affinity epibatidine binding of functional, human alpha7-nicotinic acetylcholine receptors stably and heterologously expressed de novo in human SH-EP1 cells.
Peng JH; Fryer JD; Hurst RS; Schroeder KM; George AA; Morrissy S; Groppi VE; Leonard SS; Lukas RJ
J Pharmacol Exp Ther; 2005 Apr; 313(1):24-35. PubMed ID: 15590768
[TBL] [Abstract][Full Text] [Related]
11. Laminar distribution of nicotinic receptor subtypes in human cerebral cortex as determined by [3H](-)nicotine, [3H]cytisine and [3H]epibatidine in vitro autoradiography.
Sihver W; Gillberg PG; Nordberg A
Neuroscience; 1998 Aug; 85(4):1121-33. PubMed ID: 9681951
[TBL] [Abstract][Full Text] [Related]
12. John Daly's compound, epibatidine, facilitates identification of nicotinic receptor subtypes.
Marks MJ; Laverty DS; Whiteaker P; Salminen O; Grady SR; McIntosh JM; Collins AC
J Mol Neurosci; 2010 Jan; 40(1-2):96-104. PubMed ID: 19672723
[TBL] [Abstract][Full Text] [Related]
13. Genetic deletion of the adenosine A(2A) receptor prevents nicotine-induced upregulation of α7, but not α4β2* nicotinic acetylcholine receptor binding in the brain.
Metaxas A; Al-Hasani R; Farshim P; Tubby K; Berwick A; Ledent C; Hourani S; Kitchen I; Bailey A
Neuropharmacology; 2013 Aug; 71():228-36. PubMed ID: 23583933
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological and null mutation approaches reveal nicotinic receptor diversity.
Whiteaker P; Marks MJ; Grady SR; Lu Y; Picciotto MR; Changeux JP; Collins AC
Eur J Pharmacol; 2000 Mar; 393(1-3):123-35. PubMed ID: 10771005
[TBL] [Abstract][Full Text] [Related]
15. Differential agonist inhibition identifies multiple epibatidine binding sites in mouse brain.
Marks MJ; Smith KW; Collins AC
J Pharmacol Exp Ther; 1998 Apr; 285(1):377-86. PubMed ID: 9536034
[TBL] [Abstract][Full Text] [Related]
16. Neuronal nicotinic receptor beta2 and beta4 subunits confer large differences in agonist binding affinity.
Parker MJ; Beck A; Luetje CW
Mol Pharmacol; 1998 Dec; 54(6):1132-9. PubMed ID: 9855644
[TBL] [Abstract][Full Text] [Related]
17. Postnatal upregulation of alpha4 and alpha3 nicotinic receptor subunits in the brain of alpha7 nicotinic receptor-deficient mice.
Yu WF; Guan ZZ; Nordberg A
Neuroscience; 2007 Jun; 146(4):1618-28. PubMed ID: 17434683
[TBL] [Abstract][Full Text] [Related]
18. Differential regulation of neuronal nicotinic receptor binding sites following chronic nicotine administration.
Flores CM; Dávila-García MI; Ulrich YM; Kellar KJ
J Neurochem; 1997 Nov; 69(5):2216-9. PubMed ID: 9349569
[TBL] [Abstract][Full Text] [Related]
19. Nitrogen substitution modifies the activity of cytisine on neuronal nicotinic receptor subtypes.
Carbonnelle E; Sparatore F; Canu-Boido C; Salvagno C; Baldani-Guerra B; Terstappen G; Zwart R; Vijverberg H; Clementi F; Gotti C
Eur J Pharmacol; 2003 Jun; 471(2):85-96. PubMed ID: 12818695
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of chronic drug treatment on alpha3* and alpha7 nicotinic receptor binding sites, in hippocampal neurones and SH-SY5Y cells.
Ridley DL; Rogers A; Wonnacott S
Br J Pharmacol; 2001 Aug; 133(8):1286-95. PubMed ID: 11498514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
